Chris Butler

Which way AMN Healthcare Services Inc. (NYSE:AHS) insiders are heading

AMN Healthcare Services Inc. (AHS) up 8.31 per cent in the past week, is under coverage of 8 analysts who collectively recommend a buy rating on stock. 8 of the analysts have a buy or better rating; the 0 sells versus 0 underperforms. The 8 equity analysts who rate the stock have an average target price at $45.25, with individual targets ranging between $40 and $53. The shares closed last trade at $41.17, implying that analysts see shares rising about 9.91 per cent in 12 months’ time.

Insider Activity: Insiders look pessimistic about the prospects of the company that they seem to offload shares while they are 32.59 up so far this year. A President and CEO at AMN Healthcare Services Inc. (AHS) sold shares in the company in a transaction completed on Tuesday June 07, 2016. Salka Susan R offloaded 30,000 shares in the company at an average price of $40 and ended up generating $1,200,000 in proceeds. Salka Susan R retains 318,688 shares in the company after this transaction. A Pres., Prof. Svc. & Staffing in the company, Henderson Ralph, on Monday June 06, 2016 collected $786,600 from the sale of 20,000 shares at $40 each. Insiders are expected to know better about the health and prospects of their company, which is why insiders’ move deserves attention.

Earnings to Watch: Investors considering AHS stock at the going market price of $41.17/share should know the stock will next release quarterly results for the June 2016 quarter. For the reporting quarter, analysts expect the company to deliver $0.51 in earnings per share (EPS). That would represent a 34.21% year-over-year increase. Revenue for the same period is expected to arrive at $454.87M.

Earnings Roundup: In the last fiscal quarter alone, AMN Healthcare Services Inc. generated around $468M in revenue and net income of $0.6/share. That compares with the consensus estimate $446.48M and $0.5/share, respectively. For the prior quarter revenue for the company hit $402.55M, with earnings at $0.47/share.

Analyst Coverage: Lake Street has been a brokerage house following shares of AMN Healthcare Services Inc. (AHS), so its rating change is noteworthy. The stock was initiated at Buy, wrote analysts at Lake Street, in a note issued to clients on Tuesday May 31, 2016. There was another key note issued by UBS on Tuesday March 24, 2015. The firm lifted its rating on AHS from Neutral to Buy.

Price Momentum: Despite the 1.18% increase in value, the stock’s new closing price represents a 0.41% rise in value from company’s one year high of $41.37. The stock is currently holding above its 50 day moving average of $14.53 and above its 200 day moving average of $36.73. Over the last three months and over the last six months, the shares of AMN Healthcare Services Inc. (AHS), have changed 30.73% and 31.58%, respectively.

 

Kindred Healthcare Inc. (NYSE:KND) Insider Activities Are in the Air

Kindred Healthcare Inc. (KND) up 1.98 per cent in the past week, is under coverage of 11 analysts who collectively recommend a hold rating on stock. 3 of the analysts have a buy or better rating; the 0 sells versus 1 underperforms. The 8 equity analysts who rate the stock have an average target price at $14.81, with individual targets ranging between $10 and $20. The shares closed last trade at $12.39, implying that analysts see shares rising about 19.53 per cent in 12 months’ time.

Insider Activity: Insiders look mixed about the prospects of the company that they seem to trade shares both ways while they are 6.14 up so far this year. A Director at Kindred Healthcare Inc. (KND) purchased shares in the company in a transaction completed on Tuesday November 10, 2015. Diaz Paul J accumulated 50,000 shares in the company at an average price of $12.53 and ended up spending $626,500 in the investment. Diaz Paul J now have 348,788 shares in the company after this transaction. A President & CEO in the company, Breier Benjamin A, on Monday August 31, 2015 collected $111,080 from the sale of 5,400 shares at $12.53 each. Insiders are expected to know better about the health and prospects of their company, which is why insiders’ move deserves attention.

Earnings to Watch: Investors considering KND stock at the going market price of $12.39/share should know the stock will next release quarterly results for the June 2016 quarter. For the reporting quarter, analysts expect the company to deliver $0.34 in earnings per share (EPS). That would represent a -12.82% year-over-year decrease. Revenue for the same period is expected to arrive at $1.86B.

Earnings Roundup: In the last fiscal quarter alone, Kindred Healthcare Inc. generated around $1.84B in revenue and net income of $0.25/share. That compares with the consensus estimate $1.84B and $0.22/share, respectively. For the prior quarter revenue for the company hit $1.78B, with earnings at $0.33/share.

Analyst Coverage: Avondale has been a brokerage house following shares of Kindred Healthcare Inc. (KND), so its rating change is noteworthy. The stock was downgraded to Mkt Perform from Mkt Outperform, wrote analysts at Avondale, in a note issued to clients on Friday December 18, 2015. There was another key note issued by Wells Fargo on Thursday November 05, 2015. The firm lowered its rating on KND from Outperform to Market Perform.

Price Momentum: Despite the -2.29% decrease in value, the stock’s new closing price represents a -45.04% fall in value from company’s one year high of $23.36. The stock is currently holding above its 50 day moving average of $-3.33 and below its 200 day moving average of $12.94. Over the last three months and over the last six months, the shares of Kindred Healthcare Inc. (KND), have changed -3.06% and 11.72%, respectively.

 

The Insider Activity Don’t Lie: Relypsa, Inc. (NASDAQ:RLYP)

Relypsa, Inc. (RLYP) down -3.42 per cent in the past week, is under coverage of 14 analysts who collectively recommend a buy rating on stock. 11 of the analysts have a buy or better rating; the 0 sells versus 2 underperforms. The 12 equity analysts who rate the stock have an average target price at $32, with individual targets ranging between $9 and $51. The shares closed last trade at $19.18, implying that analysts see shares rising about 66.84 per cent in 12 months’ time.

Insider Activity: Insiders look pessimistic about the prospects of the company that they seem to offload shares while they are -32.32 down so far this year. A Director at Relypsa, Inc. (RLYP) sold shares in the company in a transaction completed on Tuesday June 07, 2016. Torley Helen offloaded 1,013 shares in the company at an average price of $19.32 and ended up generating $19,570 in proceeds. Torley Helen retains 1,237 shares in the company after this transaction. A Director in the company, Spiegelman Daniel K, on Tuesday June 07, 2016 collected $19,560 from the sale of 1,013 shares at $19.32 each. Insiders are expected to know better about the health and prospects of their company, which is why insiders’ move deserves attention.

Earnings to Watch: Investors considering RLYP stock at the going market price of $19.18/share should know the stock will next release quarterly results for the June 2016 quarter. For the reporting quarter, analysts expect the company to deliver -$1.52 in earnings per share (EPS). That would represent a 60% year-over-year increase. Revenue for the same period is expected to arrive at $7.38M.

Earnings Roundup: In the last fiscal quarter alone, Relypsa, Inc. generated around $12.38M in revenue and net income of -$1.26/share. That compares with the consensus estimate $6.88M and -$1.46/share, respectively. For the prior quarter revenue for the company hit $11.96M, with earnings at -$1.4/share.

Analyst Coverage: Morgan Stanley has been a brokerage house following shares of Relypsa, Inc. (RLYP), so its rating change is noteworthy. The stock was downgraded to Underweight from Equal-Weight, wrote analysts at Morgan Stanley, in a note issued to clients on Tuesday June 07, 2016. There was another key note issued by Mizuho on Wednesday June 01, 2016. The firm lifted its rating on RLYP from Underperform to Neutral.

Price Momentum: Despite the -0.83% decrease in value, the stock’s new closing price represents a -47.55% fall in value from company’s one year high of $35.97. The stock is currently holding above its 50 day moving average of $11.96 and above its 200 day moving average of $16.83. Over the last three months and over the last six months, the shares of Relypsa, Inc. (RLYP), have changed -0.82% and 19.03%, respectively.

 

Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP) at $4.11: How much higher it can go

Synergy Pharmaceuticals, Inc. (SGYP) up 9.89 per cent in the past week, is under coverage of 5 analysts who collectively recommend a buy rating on stock. 4 of the analysts have a buy or better rating; the 0 sells versus 0 underperforms. The 5 equity analysts who rate the stock have an average target price at $9.9, with individual targets ranging between $4 and $15. The shares closed last trade at $4.11, implying that analysts see shares rising about 140.88 per cent in 12 months’ time.

Insider Activity: Insiders look pessimistic about the prospects of the company that they seem to offload shares while they are -27.51 down so far this year. A Senior Vice President, Finance at Synergy Pharmaceuticals, Inc. (SGYP) sold shares in the company in a transaction completed on Monday September 14, 2015. Denoyer Bernard offloaded 10,000 shares in the company at an average price of $7.5 and ended up generating $75,000 in proceeds. Denoyer Bernard retains 0 shares in the company after this transaction. A Director in the company, Joslyn Alan, on Friday September 11, 2015 collected $99,300 from the sale of 13,754 shares at $7.5 each. Insiders are expected to know better about the health and prospects of their company, which is why insiders’ move deserves attention.

Earnings Roundup: In the last fiscal quarter alone, Synergy Pharmaceuticals, Inc. generated around $0 in revenue and net income of -$0.29/share. That compares with the consensus estimate $0 and -$0.23/share, respectively. For the prior quarter revenue for the company hit $0, with earnings at -$0.27/share.

Analyst Coverage: Citigroup has been a brokerage house following shares of Synergy Pharmaceuticals, Inc. (SGYP), so its rating change is noteworthy. The stock was downgraded to Neutral from Buy, wrote analysts at Citigroup, in a note issued to clients on Friday December 18, 2015. There was another key note issued by Canaccord Genuity on Friday May 22, 2015. The firm launched coverage on SGYP at Buy.

Price Momentum: Despite the 0.98% increase in value, the stock’s new closing price represents a -59.51% fall in value from company’s one year high of $10.15. The stock is currently holding below its 50 day moving average of $27.32 and above its 200 day moving average of $3.35. Over the last three months and over the last six months, the shares of Synergy Pharmaceuticals, Inc. (SGYP), have changed -13.87% and 3.97%, respectively.

 

Sanchez Energy Corporation (NYSE:SN) Insiders Look Pessimistic About Prospects

Sanchez Energy Corporation (SN) up 14.5 per cent in the past week, is under coverage of 17 analysts who collectively recommend a hold rating on stock. 7 of the analysts have a buy or better rating; the 0 sells versus 0 underperforms. The 15 equity analysts who rate the stock have an average target price at $8.43, with individual targets ranging between $5 and $12. The shares closed last trade at $9.16, implying that analysts see shares falling about -7.97 per cent in 12 months’ time.

Insider Activity: Insiders look pessimistic about the prospects of the company that they seem to offload shares while they are 112.53 up so far this year. A Director at Sanchez Energy Corporation (SN) sold shares in the company in a transaction completed on Friday June 03, 2016. Jackson Alan G. offloaded 7,936 shares in the company at an average price of $8.05 and ended up generating $63,880 in proceeds. Jackson Alan G. retains 79,115 shares in the company after this transaction. A Director in the company, Carney Thomas Brian, on Friday June 03, 2016 collected $51,490 from the sale of 6,349 shares at $8.05 each. Insiders are expected to know better about the health and prospects of their company, which is why insiders’ move deserves attention.

Earnings to Watch: Investors considering SN stock at the going market price of $9.16/share should know the stock will next release quarterly results for the June 2016 quarter. For the reporting quarter, analysts expect the company to deliver -$0.09 in earnings per share (EPS). That would represent a -79.07% year-over-year decrease. Revenue for the same period is expected to arrive at $119.38M.

Earnings Roundup: In the last fiscal quarter alone, Sanchez Energy Corporation generated around $79.82M in revenue and net income of -$0.3/share. That compares with the consensus estimate $123.83M and -$0.12/share, respectively. For the prior quarter revenue for the company hit $109.53M, with earnings at $0.04/share.

Analyst Coverage: KLR Group has been a brokerage house following shares of Sanchez Energy Corporation (SN), so its rating change is noteworthy. The stock was downgraded to Hold from Buy, wrote analysts at KLR Group, in a note issued to clients on Wednesday May 11, 2016. There was another key note issued by Iberia on Wednesday April 27, 2016. The firm launched coverage on SN at Outperform.

Price Momentum: Despite the 5.05% increase in value, the stock’s new closing price represents a -16.5% fall in value from company’s one year high of $10.97. The stock is currently holding below its 50 day moving average of $21.21 and above its 200 day moving average of $8.31. Over the last three months and over the last six months, the shares of Sanchez Energy Corporation (SN), have changed 63.47% and 5.33%, respectively.

 

Analysts: Ciena Corporation (NYSE:CIEN) stock is worth $24.72

Ciena Corporation (CIEN) up 24.57 per cent in the past week, is under coverage of 20 analysts who collectively recommend a buy rating on stock. 18 of the analysts have a buy or better rating; the 0 sells versus 0 underperforms. The 16 equity analysts who rate the stock have an average target price at $24.72, with individual targets ranging between $17 and $33. The shares closed last trade at $21.75, implying that analysts see shares rising about 13.66 per cent in 12 months’ time.

Insider Activity: Insiders look pessimistic about the prospects of the company that they seem to offload shares while they are 5.12 up so far this year. A Director at Ciena Corporation (CIEN) sold shares in the company in a transaction completed on Thursday June 02, 2016. Obrien Judith M offloaded 5,000 shares in the company at an average price of $20 and ended up generating $100,000 in proceeds. Obrien Judith M retains 74,824 shares in the company after this transaction. A Sr. VP, General Counsel in the company, Rothenstein David M, on Thursday June 02, 2016 collected $79,760 from the sale of 4,000 shares at $20 each. Insiders are expected to know better about the health and prospects of their company, which is why insiders’ move deserves attention.

Earnings to Watch: Investors considering CIEN stock at the going market price of $21.75/share should know the stock will next release quarterly results for the July 2016 quarter. For the reporting quarter, analysts expect the company to deliver $0.38 in earnings per share (EPS). That would represent a 2.7% year-over-year increase. Revenue for the same period is expected to arrive at $672.6M.

Earnings Roundup: In the last fiscal quarter alone, Ciena Corporation generated around $640.72M in revenue and net income of $0.34/share. That compares with the consensus estimate $630.74M and $0.27/share, respectively. For the prior quarter revenue for the company hit $573.11M, with earnings at $0.18/share.

Analyst Coverage: Drexel Hamilton has been a brokerage house following shares of Ciena Corporation (CIEN), so its rating change is noteworthy. The stock was initiated at Buy, wrote analysts at Drexel Hamilton, in a note issued to clients on Friday April 08, 2016. There was another key note issued by Citigroup on Wednesday January 27, 2016. The firm launched coverage on CIEN at Neutral.

Price Momentum: Despite the 2.26% increase in value, the stock’s new closing price represents a -17.92% fall in value from company’s one year high of $26.5. The stock is currently holding below its 50 day moving average of $25.14 and above its 200 day moving average of $17.1. Over the last three months and over the last six months, the shares of Ciena Corporation (CIEN), have changed 8.06% and 18.84%, respectively.

Current Range Resources Corporation (NYSE:RRC) PT Means Stock Is Worth Almost $62

Range Resources Corporation (RRC) up 8.52 per cent in the past week, is under coverage of 36 analysts who collectively recommend a hold rating on stock. 20 of the analysts have a buy or better rating; the 0 sells versus 0 underperforms. The 32 equity analysts who rate the stock have an average target price at $46.16, with individual targets ranging between $33 and $62. The shares closed last trade at $46.22, implying that analysts see shares falling about -0.13 per cent in 12 months’ time.

Insider Activity: Insiders look pessimistic about the prospects of the company that they seem to offload shares while they are 87.93 up so far this year. A Director at Range Resources Corporation (RRC) sold shares in the company in a transaction completed on Thursday May 26, 2016. Dub Anthony V offloaded 5,000 shares in the company at an average price of $41.61 and ended up generating $208,050 in proceeds. Dub Anthony V retains 110,458 shares in the company after this transaction. A Sr. VP & General Counsel in the company, Poole David P, on Wednesday May 25, 2016 collected $384,510 from the sale of 8,942 shares at $41.61 each. Insiders are expected to know better about the health and prospects of their company, which is why insiders’ move deserves attention.

Earnings to Watch: Investors considering RRC stock at the going market price of $46.22/share should know the stock will next release quarterly results for the June 2016 quarter. For the reporting quarter, analysts expect the company to deliver -$0.21 in earnings per share (EPS). That would represent a -2200% year-over-year decrease. Revenue for the same period is expected to arrive at $327.39M.

Earnings Roundup: In the last fiscal quarter alone, Range Resources Corporation generated around $353.97M in revenue and net income of -$0.1/share. That compares with the consensus estimate $319.86M and -$0.19/share, respectively. For the prior quarter revenue for the company hit $415.86M, with earnings at $0.25/share.

Analyst Coverage: Raymond James has been a brokerage house following shares of Range Resources Corporation (RRC), so its rating change is noteworthy. The stock was upgraded to Outperform from Mkt Perform, wrote analysts at Raymond James, in a note issued to clients on Tuesday May 17, 2016. There was another key note issued by KLR Group on Monday May 02, 2016. The firm lowered its rating on RRC from Buy to Accumulate.

Price Momentum: Despite the 2.62% increase in value, the stock’s new closing price represents a -17.39% fall in value from company’s one year high of $55.17. The stock is currently holding above its 50 day moving average of $18.32 and above its 200 day moving average of $41.46. Over the last three months and over the last six months, the shares of Range Resources Corporation (RRC), have changed 43.28% and 31.48%, respectively.

 

Analysts: Flexion Therapeutics, Inc. (NASDAQ:FLXN) stock is worth $36.5

Flexion Therapeutics, Inc. (FLXN) down -16.22 per cent in the past week, is under coverage of 7 analysts who collectively recommend a buy rating on stock. 7 of the analysts have a buy or better rating; the 0 sells versus 0 underperforms. The 6 equity analysts who rate the stock have an average target price at $36.5, with individual targets ranging between $30 and $44. The shares closed last trade at $14.1, implying that analysts see shares rising about 158.87 per cent in 12 months’ time.

Insider Activity: Insiders look optimistic about the prospects of the company that they seem to accumulate shares while they are -26.83 down so far this year. A President and CEO at Flexion Therapeutics, Inc. (FLXN) purchased shares in the company in a transaction completed on Friday May 20, 2016. Clayman Michael D. accumulated 2,000 shares in the company at an average price of $10.41 and ended up spending $20,820 in the investment. Clayman Michael D. now have 705,512 shares in the company after this transaction. A President and CEO in the company, Clayman Michael D., on Thursday May 19, 2016 spent $19,300 from the purchase of 2,000 shares at $10.41 each. Insiders are expected to know better about the health and prospects of their company, which is why insiders’ move deserves attention.

Earnings Roundup: In the last fiscal quarter alone, Flexion Therapeutics, Inc. generated around $0 in revenue and net income of -$0.78/share. That compares with the consensus estimate $0 and -$0.61/share, respectively. For the prior quarter revenue for the company hit $0, with earnings at -$0.63/share.

Analyst Coverage: Cantor Fitzgerald has been a brokerage house following shares of Flexion Therapeutics, Inc. (FLXN), so its rating change is noteworthy. The stock was initiated at Buy, wrote analysts at Cantor Fitzgerald, in a note issued to clients on Wednesday November 04, 2015. There was another key note issued by Northland Capital on Thursday May 14, 2015. The firm launched coverage on FLXN at Outperform.

Price Momentum: Despite the -12.37% decrease in value, the stock’s new closing price represents a -51.53% fall in value from company’s one year high of $29.09. The stock is currently holding below its 50 day moving average of $19.03 and above its 200 day moving average of $12.12. Over the last three months and over the last six months, the shares of Flexion Therapeutics, Inc. (FLXN), have changed -8.09% and 13.51%, respectively.

 

Analysts: First Niagara Financial Group Inc. (NASDAQ:FNFG) stock is worth $11

 

First Niagara Financial Group Inc. (FNFG) down -0.55 per cent in the past week, is under coverage of 13 analysts who collectively recommend a hold rating on stock. 2 of the analysts have a buy or better rating; the 0 sells versus 2 underperforms. The 11 equity analysts who rate the stock have an average target price at $11, with individual targets ranging between $8 and $13. The shares closed last trade at $10.86, implying that analysts see shares rising about 1.29 per cent in 12 months’ time.

Insider Activity: Insiders look pessimistic about the prospects of the company that they seem to offload shares while they are 1.71 up so far this year. A Chief Information Officer at First Niagara Financial Group Inc. (FNFG) sold shares in the company in a transaction completed on Thursday June 02, 2016. Koul Inder offloaded 238 shares in the company at an average price of $11.04 and ended up generating $2,630 in proceeds. Koul Inder retains 112,585 shares in the company after this transaction. A EVP, Managing Dir HR in the company, White Kate, on Friday May 27, 2016 collected $11,670 from the sale of 1,070 shares at $11.04 each. Insiders are expected to know better about the health and prospects of their company, which is why insiders’ move deserves attention.

Earnings to Watch: Investors considering FNFG stock at the going market price of $10.86/share should know the stock will next release quarterly results for the June 2016 quarter. For the reporting quarter, analysts expect the company to deliver $0.15 in earnings per share (EPS). That would represent a 0% year-over-year decrease. Revenue for the same period is expected to arrive at $356.17M.

Earnings Roundup: In the last fiscal quarter alone, First Niagara Financial Group Inc. generated around $346.66M in revenue and net income of $0.11/share. That compares with the consensus estimate $351.25M and $0.14/share, respectively. For the prior quarter revenue for the company hit $355.95M, with earnings at $0.12/share.

Analyst Coverage: Standpoint Research has been a brokerage house following shares of First Niagara Financial Group Inc. (FNFG), so its rating change is noteworthy. The stock was downgraded to Hold from Buy, wrote analysts at Standpoint Research, in a note issued to clients on Friday November 13, 2015. There was another key note issued by Goldman on Monday November 02, 2015. The firm lifted its rating on FNFG from Sell to Neutral.

Price Momentum: Despite the -0.82% decrease in value, the stock’s new closing price represents a -1.99% fall in value from company’s one year high of $11.22. The stock is currently holding above its 50 day moving average of $5.64 and above its 200 day moving average of $10.59. Over the last three months and over the last six months, the shares of First Niagara Financial Group Inc. (FNFG), have changed 8.93% and 10.14%, respectively.